Avisi Technologies featured at LSI’s 2024 US Emerging Medtech Summit. Dr. Catherine Mohr delivers the keynote presentation.

Avisi Technologies Featured at LSI’s 2024 US Emerging Medtech Summit in Keynote Presentation

Summary of Avisi Involvement as Presenting Company 2024 and 2023 Panel Representation Avisi Technologies returned to the 2024 US Emerging Medtech Summit with updates about the development of VisiPlate, a nanotechnology-enabled aqueous shunt for the treatment of glaucoma. Avisi generated buzz in the Life Science Intelligence (LSI) community by announcing exclusive clinical data, showing promising […]

Illustration of a doctor examining a patient's eye for glaucoma, representing the work of the South African Glaucoma Society and advancements in glaucoma treatment.

VisiPlate® Aqueous Shunt Safety and Effectiveness data from VITA Clinical Trial to be presented at the 2024 South Africa Glaucoma Society Annual Congress

Interim trial results demonstrate the safety and effectiveness of VisiPlate® as a standalone treatment for primary open-angle glaucoma.   REDWOOD CITY, Calif., (May 14, 2024) – Avisi Technologies, Inc., an ophthalmic-focused medical device manufacturer, is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Avisi’s flagship product, VisiPlate, is a nanotechnology-enabled implant […]

1 3 4 5

Subscribe for latest news and updates

    Skip to content